Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RESET-SSc
NCT06328777Phase 3Recruiting
- Sponsor
- Cabaletta Bio
- Start
- Jul 2024
- Primary completion
- Jul 2029
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 3, open-label trial of resecabtagene autoleucel in systemic sclerosis (SSc) (2 arms), sponsored by Cabaletta Bio. Primary endpoints: Incidence of adverse events at 28 days and Percent predicted forced vital capacity at 52 weeks. Started Jul 2024; status: recruiting.
02
Drugs
resecabtagene autoleucel
03
Conditions
systemic sclerosis (SSc)
Beyond the preview
Go deeper on NCT06328777.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06328777.